• Publications
  • Influence
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.
  • S. Roffey, S. Cole, +6 authors N. Wood
  • Biology, Medicine
  • Drug metabolism and disposition: the biological…
  • 1 June 2003
Voriconazole is a new triazole antifungal agent with potent, wide-spectrum activity. Its pharmacokinetics and metabolism have been studied in mouse, rat, rabbit, dog, guinea pig, and humans afterExpand
  • 266
  • 18
  • PDF
SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV
UK-427,857 (4, 4-difluoro-N-{(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide) is a novel CCR5 antagonist undergoingExpand
  • 157
  • 11
  • PDF
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
AIMS Two studies were conducted to: (i) quantify the amount of drug-related radioactivity in blood, plasma, urine and faeces following a (14)C-labelled dose of maraviroc; and (ii) investigate theExpand
  • 84
  • 11
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
An early understanding of key metabolites of drugs is crucial in drug discovery and development. As a result, several in vitro models typically derived from liver are frequently used to study drugExpand
  • 146
  • 9
Analytical strategies for identifying drug metabolites.
With the dramatic increase in the number of new chemical entities (NCEs) arising from combinatorial chemistry and modern high-throughput bioassays, novel bioanalytical techniques are required for theExpand
  • 236
  • 6
In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
Drug induced toxicity remains one of the major reasons for failures of new pharmaceuticals, and for the withdrawal of approved drugs from the market. Efforts are being made to reduce attrition ofExpand
  • 61
  • 2
Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
The conduct of excretion and metabolism studies using radiolabelled drugs in multiple laboratory animal species has been a mainstay of the suite of support activities provided by drug metabolismExpand
  • 44
  • 2
The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in theExpand
  • 21
  • 2
  • PDF
From definition to implementation: a cross-industry perspective of past, current and future MIST strategies
The article describes and discusses the evolution of strategies to characterize metabolites in support of safety studies over the last 40 years, as well as future trends. Approaches to deriveExpand
  • 36
  • 2
A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
TLDR
The subject of metabolites in safety testing has had much debate in the recent past and has shown itself to be a complex issue with no simple solutions. Expand
  • 55
  • 1
  • PDF